A Study Assessing Rocatinlimab (AMG 451) Monotherapy in Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-Horizon)

Name: A Study Assessing Rocatinlimab (AMG 451) Monotherapy in Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-Horizon)
Published: 2022
License: Public Domain

Amgen · 2022

ClinicalTrials.gov · Datasets · License: Public Domain · 2022

Open Source ↗

atopic-dermatitis

atopic dermatitis, amg 451, khk 4083, eczema, rocatinlimab, interventional, phase3

This document is indexed with metadata only — full text is not available in the archive for this record. Open the official source ↗

A Study Assessing Rocatinlimab (AMG 451) Monotherapy in Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-Horizon)

Related documents